Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
株式のランク #174
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity,... Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
株価
$62.26
最終同期: 2026-09-22
時価総額
$127.18B
変化(1日)
-0.78%
変化(1年)
38.63%
US
取引 Bristol-Myers Squibb Company (BMY)

カテゴリー

Bristol-Myers Squibb Company(BMY)の利益
Jun 2026 時点の利益 TTM: $11.91B
Bristol-Myers Squibb Company の最新の財務報告によると、同社の現在の利益は $11.91B です。2024 年には $-8.38B の利益を上げ、これは 2023 年の利益 $8.44B と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Bristol-Myers Squibb Company の利益の推移(2000 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $11.91B 27.68%
2025 $9.33B -211.33%
2024 $-8.38B -199.28%
2023 $8.44B 9.43%
2022 $7.71B -4.75%
2021 $8.10B -217.86%
2020 $-6.87B -238.11%
2019 $4.98B -16.64%
2018 $5.97B 16.31%
2017 $5.13B -13.25%
2016 $5.92B 184.79%
2015 $2.08B -12.77%
2014 $2.38B -17.64%
2013 $2.89B 23.55%
2012 $2.34B -66.48%
2011 $6.98B 14.99%
2010 $6.07B 8.37%
2009 $5.60B 17.29%
2008 $4.78B 35.14%
2007 $3.53B 47.25%
2006 $2.40B -44.24%
2005 $4.30B -2.58%
2004 $4.42B -5.60%
2003 $4.68B 69.50%
2002 $2.76B 24.48%
2001 $2.22B -59.51%
2000 $5.48B 0.00%
同業他社の利益
企業 利益 利益の差
$33.60B 182.08%
US
$25.20B 111.55%
US
$8.70B -26.96%
US
$21.39B 79.58%
CH
$5.95B -50.06%
US